![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC26A6 |
Gene summary for SLC26A6 |
![]() |
Gene information | Species | Human | Gene symbol | SLC26A6 | Gene ID | 65010 |
Gene name | solute carrier family 26 member 6 | |
Gene Alias | SLC26A6 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A0C4DFT5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
65010 | SLC26A6 | HCC1_Meng | Human | Liver | HCC | 3.68e-16 | 3.86e-02 | 0.0246 |
65010 | SLC26A6 | HCC1 | Human | Liver | HCC | 8.47e-07 | 2.84e+00 | 0.5336 |
65010 | SLC26A6 | HCC2 | Human | Liver | HCC | 8.29e-17 | 3.71e+00 | 0.5341 |
65010 | SLC26A6 | S014 | Human | Liver | HCC | 1.38e-03 | 2.39e-01 | 0.2254 |
65010 | SLC26A6 | S015 | Human | Liver | HCC | 1.92e-09 | 5.18e-01 | 0.2375 |
65010 | SLC26A6 | S016 | Human | Liver | HCC | 1.39e-03 | 2.68e-01 | 0.2243 |
65010 | SLC26A6 | S027 | Human | Liver | HCC | 6.26e-06 | 5.99e-01 | 0.2446 |
65010 | SLC26A6 | S028 | Human | Liver | HCC | 4.20e-19 | 7.97e-01 | 0.2503 |
65010 | SLC26A6 | S029 | Human | Liver | HCC | 7.21e-27 | 1.13e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
GO:005159121 | Liver | HCC | response to cAMP | 57/7958 | 93/18723 | 1.96e-04 | 1.52e-03 | 57 |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:007133112 | Liver | HCC | cellular response to hexose stimulus | 85/7958 | 153/18723 | 7.47e-04 | 4.52e-03 | 85 |
GO:007132612 | Liver | HCC | cellular response to monosaccharide stimulus | 85/7958 | 154/18723 | 9.78e-04 | 5.68e-03 | 85 |
GO:007132212 | Liver | HCC | cellular response to carbohydrate stimulus | 89/7958 | 163/18723 | 1.19e-03 | 6.62e-03 | 89 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
GO:00508926 | Liver | HCC | intestinal absorption | 25/7958 | 41/18723 | 1.31e-02 | 4.69e-02 | 25 |
GO:00713205 | Liver | HCC | cellular response to cAMP | 31/7958 | 53/18723 | 1.37e-02 | 4.87e-02 | 31 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC26A6 | SNV | Missense_Mutation | rs775888818 | c.137N>A | p.Arg46His | p.R46H | Q9BXS9 | protein_coding | tolerated(0.63) | benign(0) | TCGA-KK-A59V-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
SLC26A6 | SNV | Missense_Mutation | c.1535A>G | p.His512Arg | p.H512R | Q9BXS9 | protein_coding | tolerated(0.64) | benign(0.003) | TCGA-B7-5816-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC26A6 | SNV | Missense_Mutation | c.1936N>A | p.Gly646Ser | p.G646S | Q9BXS9 | protein_coding | tolerated(0.23) | benign(0.011) | TCGA-BR-8682-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
SLC26A6 | SNV | Missense_Mutation | rs549074921 | c.1099N>A | p.Ala367Thr | p.A367T | Q9BXS9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
SLC26A6 | SNV | Missense_Mutation | c.869N>T | p.Gln290Leu | p.Q290L | Q9BXS9 | protein_coding | deleterious(0.01) | benign(0.071) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
SLC26A6 | SNV | Missense_Mutation | novel | c.601N>T | p.Ile201Phe | p.I201F | Q9BXS9 | protein_coding | deleterious(0) | benign(0.284) | TCGA-RD-A8N6-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
SLC26A6 | deletion | Frame_Shift_Del | c.1618delG | p.Val540Ter | p.V540* | Q9BXS9 | protein_coding | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
SLC26A6 | insertion | Frame_Shift_Ins | rs780816364 | c.1618_1619insG | p.Val540GlyfsTer16 | p.V540Gfs*16 | Q9BXS9 | protein_coding | TCGA-CG-4460-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |